<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308123">
  <stage>Registered</stage>
  <submitdate>26/06/2009</submitdate>
  <approvaldate>2/07/2009</approvaldate>
  <actrnumber>ACTRN12609000527268</actrnumber>
  <trial_identification>
    <studytitle>A prospective, randomised study comparing the use of Actifuse (trademark) Advanced Bone MatriX (ABX) synthetic bone substitute with INFUSE (registered trademark) in patients requiring posterolateral instrumented lumbar fusion with interbody fusion</studytitle>
    <scientifictitle>A prospective, randomised study comparing the use of Actifus (trademark) Advanced Bone MatriX (ABX) synthetic bone substitute with INFUSE (registered trademark) on fusion in patients requiring posterolateral instrumented lumbar fusion with interbody fusion.</scientifictitle>
    <utrn />
    <trialacronym>APPRAISE T1 (A Prospective PLF Randomised Actifuse InfuSe Evaluation Trial 1)</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Degenerative disc disease that can be treated using Posterior Lumbar Interbody Fusion with Posterolateral Intertransverse Process Fusion and Internal Fixation achieved by pedicle screws and rods.</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Surgical techniques</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Posterior Lumbar Interbody Fusion with Posterolateral Intertransverse Process Fusion and Internal Fixation achieved by pedicle screws and rods and bone graft substitute (Actifuse ABX), with the bone graft substitute laid on between the decorticated transverse processes of the spine.</interventions>
    <comparator>The same fusion procedure using recombinant human bone morphogenetic protein 2 (rhBMP-2) also referred to as INFUSE (trademark) as the bone graft substitute</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Fusion as assessed by Computed Tomography (CT) scan</outcome>
      <timepoint>1 year following procedure</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical outcome measurements including:
Pain using Visual Analogue Scores (VAS)
Disability Status using Oswestry Low Back Pain Disability Index Questionnaire
Quality of Life using 36 item Short Form Health Survey SF36</outcome>
      <timepoint>1 year following procedure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Has degenerative disc disease of the lumbar spine as indicated by back pain of discogenic/degenerative origin, with or without leg pain, and has one or more of the following conditions as documented by plain X-rays, CT scan or Magnetic Resonance Imaging (MRI) scan:
a)Modic changes.
b)High intensity changes in the annulus.
c)Loss of disc height.
d)Decreased hydration of the disc.
e)Canal stenosis with or without spondylotic slip.
f)Gross facet joint changes requiring fusion for treatment.
g)Have documented annular pathology by other means. (e.g., with discography).
Has a preoperative Oswestry Back Disability Score of 30 or more.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Has had previous failed attempts at fusion surgery at the involved level(s).
Has a diagnosis of spinal infection tumour or trauma.
Requires surgery at more than two (2) levels.
Has osteoporosis (excluding osteopenia) as evidenced on plain X-rays, CT scans (or Dual X-ray Absorptometry (DEXA) scan in cases of doubt).
Is pregnant.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>27/06/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>ApaTech Ltd</primarysponsorname>
    <primarysponsoraddress>370 Centennial Avenue
Elstree
Hertfordshire
WD6 3TJ</primarysponsoraddress>
    <primarysponsorcountry>United Kingdom</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>ApaTech Ltd</fundingname>
      <fundingaddress>370 Centennial Avenue
Elstree
Hertfordshire
WD6 3TJ</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Perficio Clinical &amp; Regulatory Pty Ltd</sponsorname>
      <sponsoraddress>PO Box 2050
Clovelly NSW 2031</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mr L Crossley</name>
      <address>ApaTech Ltd
370 Centennial Avenue
Elstree
Hertfordshire
WD6 3TJ</address>
      <phone>+44 208 731 4640</phone>
      <fax />
      <email>lyndon.crossley@apatech.com</email>
      <country>United Kingdom</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mr L Crossley</name>
      <address>ApaTech Ltd
370 Centennial Avenue
Elstree
Hertfordshire
WD6 3TJ</address>
      <phone>+44 208 7314640</phone>
      <fax />
      <email>lyndon.crossley@apatech.com</email>
      <country>United Kingdom</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>